MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company targeting liver-related cardiometabolic diseases, announced additional interim results from Part 3B of its Phase 1 clinical trial of DA-1726.
• MTVA stock is holding steady today. What’s next for MTVA stock?
After 16 weeks of once-weekly treatment, the investigational therapy achieved a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid from baseline in otherwise healthy adults with obesity.
Uric Acid and Cardiometabolic Trial Results
By Day 109, the 15 participants receiving DA-1726 posted a mean serum uric acid drop of 1.02 mg/dL from a 5.89 mg/dL baseline.
Conversely, the four placebo participants saw levels rise by 0.45 mg/dL from a 4.80 mg/dL baseline, yielding the 1.47 mg/dL placebo-adjusted reduction.
These results complement earlier Part 3B interim data at Day 109 showing a 68.1% placebo-adjusted liver fat reduction and 13.5% placebo-adjusted weight loss.
Treatment also cut HbA1c by 0.44 absolute percentage points (p=0.006), or 0.24 percentage points placebo-adjusted, while lowering visceral and subcutaneous adipose tissue and relatively preserving lean mass.
All five DA-1726-treated participants with baseline liver steatosis reached MRI-PDFF below 5% by Day 109.
Phase 1 Study Design and Mechanism
The 16-week, randomized, placebo-controlled Part 3B trial evaluated once-weekly subcutaneous injections of DA-1726. Clinicians titrated patients from 16 mg for four weeks to 32 mg for four weeks before reaching a 64 mg target dose.
An MRI substudy assessed liver fat by MRI-PDFF and body composition across 12 treated and four placebo participants.
As a novel oxyntomodulin analog, DA-1726 acts as a dual agonist of GLP-1 (GLP1R) and glucagon (GCGR) receptors with a 3:1 potency ratio.
This design pairs GLP1R effects on appetite and glucose control with GCGR effects on energy expenditure and fat breakdown, concentrating heavily in adipose tissue and the liver during preclinical studies.
Phase 2 Liver Disease Plans
MetaVia plans a 48-week, non-biopsy Phase 2 trial of DA-1726 in Metabolic and Alcohol-Associated Liver Disease and Alcohol-Associated Liver Disease, targeting initiation in the second half of 2027.
MTVA Price Action: MetaVia shares were down 7.64% to $1.33 at the time of publication on Thursday. The stock is near its 52-week low of 97 cents, according to Benzinga Pro data.
Image via Shutterstock
